The effects of dienogest and combined oral contraceptives on protein S-specific activity in endometriosis patients
Open Access
- 29 January 2024
- journal article
- research article
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 295, 67-74
Abstract
No abstract availableKeywords
Funding Information
- Mochida Pharmaceutical Co Ltd
This publication has 22 references indexed in Scilit:
- Molecular basis of protein S deficiency in ChinaAmerican Journal of Hematology, 2013
- Activated Protein C Anticoagulant System Dysfunction and Thrombophilia in AsiaAnnals of Laboratory Medicine, 2013
- Down-regulation of PROS1 Gene Expression by 17β-Estradiol via Estrogen Receptor α (ERα)-Sp1 Interaction Recruiting Receptor-interacting Protein 140 and the Corepressor-HDAC3 ComplexJournal of Biological Chemistry, 2010
- Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosisThrombosis Research, 2009
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profileSteroids, 2008
- Upregulation of protein S by progestinsJournal of Thrombosis and Haemostasis, 2007
- Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutationsBritish Journal of Haematology, 2007
- Protein S–K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patientsBlood, 2006
- Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptivesBritish Journal of Haematology, 1997
- Familial protein S deficiency is associated with recurrent thrombosis.Journal of Clinical Investigation, 1984